Skip to main content
SpringerLink
Log in
Book cover

Resistance to Proteasome Inhibitors in Cancer

Molecular Mechanisms and Strategies to Overcome Resistance

  • Book
  • © 2014

Overview

Editors:
  1. Q. Ping Dou

    1. Wayne State University, Detroit, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Reveals latest discoveries related to the molecular mechanisms of proteasome inhibitor resistance
  • Discusses proteasome inhibitor resistance in multiple contexts, including multiple myeloma, leukemia, mantle cell lymphoma, melanoma and other cancers
  • Explores multiple, cutting-edge strategies to overcome resistance
  • Includes supplementary material: sn.pub/extras

Part of the book series: Resistance to Targeted Anti-Cancer Therapeutics (RTACT)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (15 chapters)

  1. Front Matter

    Pages i-xi
    Download chapter PDF

  2. Proteasome Inhibitors and Lessons Learned from Their Mechanisms of Action and Resistance in Human Cancer

    • Sara M. Schmitt, Rahul R. Deshmukh, Q. Ping Dou
    Pages 1-46

  3. Resistance to Proteasome Inhibitors in Multiple Myeloma

    • Francesca Cottini, Anna Guidetti, Claudia Paba Prada, Teru Hideshima, Michelle Maglio, Cindy Varga et al.
    Pages 47-80

  4. Overcoming Bortezomib Resistance: A Review of the Second-Generation Proteasome Inhibitor Carfilzomib in the Treatment of Multiple Myeloma

    • Hans C. Lee, Robert Z. Orlowski
    Pages 81-98

  5. Proteasome Inhibitors in the Treatment of Multiple Myeloma and AL Amyloidosis

    • Jeffrey A. Zonder
    Pages 99-115

  6. Profiling Bortezomib Resistance in Multiple Myeloma: Implications in Personalized Pharmacotherapy

    • Amit Kumar Mitra, Holly Stessman, John Shaughnessy, Brian Van Ness
    Pages 117-147

  7. Targeting Mantle Cell Lymphoma with a Strategy of Combined Proteasome and Histone Deacetylase Inhibition

    • Michael Batalo, Prithviraj Bose, Beata Holkova, Steven Grant
    Pages 149-179

  8. Preclinical Studies on the Molecular Basis of Bortezomib Resistance and Modalities to Overcome Resistance in Hematological Malignancies

    • Jacqueline Cloos, Denise Niewerth, Gerrit Jansen
    Pages 181-204

  9. Overcoming Inherent Resistance to Proteasome Inhibitors in Head and Neck Cancer: Challenges and New Approaches

    • Jason I. Kass, Jennifer R. Grandis, Daniel E. Johnson
    Pages 205-231

  10. Targeting the Proteasome Pathway for the Treatment of Solid Tumors

    • Nisar Ahmad, Elias Anaissie, Mohamed A. Y. Abdel Malek, James J. Driscoll
    Pages 233-248

  11. Oxidative Stress and the Proteasome: Mechanisms and Therapeutic Relevance

    • Christa Manton, Joya Chandra
    Pages 249-274

  12. Proteotoxic Stress and Proteasome Inhibitor Efficacy and Resistance

    • David McConkey
    Pages 275-289

  13. Proteasome Inhibitors Versus E3 Ligase Inhibitors for Cancer Therapy

    • Michael R. Mattern, Michael J. Eddins, Saket Agarwal, David E. Sterner, Matthew P. Kodrasov, K. G. Suresh Kumar et al.
    Pages 291-316

  14. Novel Ubiquitin E3 Ligases as Targets for Cancer Therapy: Focus on Breast Cancer-Associated Gene 2 (BCA2)

    • Yutaka Amemiya, Stephanie Bacopulos, Arun Seth
    Pages 317-346

  15. The 26S Proteasomal ATPases: Structure, Function, Regulation, and Potential for Cancer Therapies

    • Young-Chan Kim, David M. Smith
    Pages 347-364

  16. Deubiquitinating Enzymes as Novel Targets for Cancer Therapies

    • Kwang-Hyun Baek, Key-Hwan Lim, Jang-Joon Park
    Pages 365-385

  17. Back Matter

    Pages 387-390
    Download chapter PDF
Back to top

Keywords

About this book

The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.

This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.

Editors and Affiliations

  • Wayne State University, Detroit, USA

    Q. Ping Dou

About the editor

Q. Ping Dou, Ph.D. is Professor of Pathology, Cancer Biology and Pharmacology at Wayne State University School of Medicine. Dr. Dou's laboratory is one of the first to report that proteasome inhibitors rapidly induce tumor cell apoptosis, selectively activate the cell death program in oncogene-transformed, but not normal or untransformed cells and are able to trigger apoptotic death in human cancer cells that are resistant to various anticancer agents. He also serves on multiple editorial boards, including The Open Leukemia Journal, Journal of Clinical Oncology, Frontiers of Bioscience, to name a few.

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation